SPP1 and bladder transitional cell carcinoma: The SPP1 level apparently increased in cholangiocarcinoma (CHOL), breast invasive carcinoma (BRCA), bladder urothelial carcinoma (BLCA), COAD, ESCA, HNSC, liver hepatocellular carcinoma (LIHC), kidney renal papillary cell carcinoma (KIRP), LUSC, LUAD, rectum adenocarcinoma (READ), prostate adenocarcinoma (PRAD), thyroid carcinoma (THCA), uterine corpus endometrial carcinoma (UCEC), and stomach adenocarcinoma (STAD), in comparison with the non-carcinoma samples.